Patented Medicine Prices Review Board 2024–25 Departmental Results Report

The Patented Medicine Prices Review Board’s 2024–25 Departmental Results Report measures the department's performance against its stated plans and priorities. It was published by the Patented Medicine Prices Review Board Canada and last updated on 2026-04-16. The report is available in HTML format under the OGL-CA-2.0 license.

Use Cases

• Assess regulatory agency performance based on reported departmental results
• Analyze pharmaceutical pricing policy implementation based on performance metrics
• Track government accountability and transparency based on published plans and outcomes

Strengths

• Report is published by the official Canadian regulatory body for patented medicine prices.
• Data is provided under the permissive OGL-CA-2.0 license for reuse.

Limitations

• Description metadata is limited; actual data quality requires manual inspection after download.
• Column-level documentation is absent; field semantics must be inferred after download.
• Row count and specific data structure are unknown, which may limit suitability assessment.

Provenance

Source

Patented Medicine Prices Review Board Canada | Conseil d'examen du prix des médicaments brevetés Canada

Time Range

2024–25 fiscal period

Freshness

Last updated 2026-04-16 19:42:45.391447; freshness should be verified.

Geography

Canada